| Literature DB >> 32703874 |
Joshua Pottel1, Duncan Armstrong2, Ling Zou3, Alexander Fekete2, Xi-Ping Huang4, Hayarpi Torosyan1, Dallas Bednarczyk5, Steven Whitebread2, Barun Bhhatarai5, Guiqing Liang5, Hong Jin2, S Nassir Ghaemi6,7,8, Samuel Slocum4, Katalin V Lukacs9, John J Irwin1, Ellen L Berg10, Kathleen M Giacomini3, Bryan L Roth4, Brian K Shoichet11, Laszlo Urban12.
Abstract
Excipients, considered "inactive ingredients," are a major component of formulated drugs and play key roles in their pharmacokinetics. Despite their pervasiveness, whether they are active on any targets has not been systematically explored. We computed the likelihood that approved excipients would bind to molecular targets. Testing in vitro revealed 25 excipient activities, ranging from low-nanomolar to high-micromolar concentration. Another 109 activities were identified by testing against clinical safety targets. In cellular models, five excipients had fingerprints predictive of system-level toxicity. Exposures of seven excipients were investigated, and in certain populations, two of these may reach levels of in vitro target potency, including brain and gut exposure of thimerosal and its major metabolite, which had dopamine D3 receptor dissociation constant K d values of 320 and 210 nM, respectively. Although most excipients deserve their status as inert, many approved excipients may directly modulate physiologically relevant targets.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32703874 PMCID: PMC7960226 DOI: 10.1126/science.aaz9906
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728